• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 5. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788

Introduction to 1-Naphthalenecarboxaldehyde 4-(trifluoromethyl) (CAS No. 1261596-97-7)

1-Naphthalenecarboxaldehyde 4-(trifluoromethyl), identified by its Chemical Abstracts Service (CAS) number 1261596-97-7, is a fluorinated aromatic aldehyde that has garnered significant attention in the field of pharmaceutical and chemical research. This compound, characterized by its naphthalene core substituted with a formyl group at the 1-position and a trifluoromethyl group at the 4-position, exhibits unique structural and electronic properties that make it a valuable intermediate in synthetic chemistry and a promising candidate for drug development.

The naphthalene scaffold is a well-documented motif in medicinal chemistry, known for its ability to interact with biological targets through hydrophobic and π-stacking interactions. The introduction of a trifluoromethyl group at the 4-position of the naphthalene ring enhances the lipophilicity and metabolic stability of the molecule, which are critical factors in drug design. Additionally, the presence of a formyl group (-CHO) provides a reactive site for further functionalization, enabling the synthesis of more complex derivatives.

Recent advancements in computational chemistry and molecular modeling have highlighted the potential of fluorinated aromatic aldehydes like 1-Naphthalenecarboxaldehyde 4-(trifluoromethyl) as key building blocks in the development of novel therapeutic agents. Studies have demonstrated that such compounds can exhibit enhanced binding affinity to biological targets, improved pharmacokinetic profiles, and increased resistance to metabolic degradation. These properties are particularly relevant in the quest for more effective treatments for diseases such as cancer, inflammation, and infectious disorders.

In particular, the trifluoromethyl substituent has been shown to modulate electronic effects and steric interactions, influencing both the reactivity and selectivity of biochemical pathways. This has led to its incorporation into various drug candidates targeting enzymes such as kinases and proteases. For instance, recent research has explored the use of 1-Naphthalenecarboxaldehyde 4-(trifluoromethyl) as a precursor in the synthesis of inhibitors designed to disrupt aberrant signaling pathways involved in tumor growth and progression.

The formyl group of this compound also serves as a versatile handle for further chemical modifications. It can be readily converted into other functional groups such as amides, esters, or thioesters through condensation reactions with appropriate reagents. These derivatives have been investigated for their potential as prodrugs or as intermediates in the synthesis of more complex molecules with tailored biological activities.

From a synthetic chemistry perspective, 1-Naphthalenecarboxaldehyde 4-(trifluoromethyl) exemplifies an elegant example of how structural modifications can enhance molecular properties. The compound can be synthesized through various routes, including Friedel-Crafts acylation followed by selective reduction or direct functionalization strategies employing fluorinating agents. These synthetic methodologies not only highlight the versatility of fluorinated aromatic systems but also provide valuable insights into optimizing reaction conditions for industrial-scale production.

The growing interest in fluorinated compounds stems from their widespread utility across multiple therapeutic areas. In oncology, for example, drugs containing trifluoromethyl groups have shown remarkable efficacy due to their ability to improve target binding and reduce off-target effects. Similarly, in anti-inflammatory therapies, these compounds have been engineered to modulate cytokine production and immune responses. The naphthalenecarboxaldehyde moiety contributes to these effects by providing a scaffold that can be fine-tuned through structural variations to achieve desired pharmacological outcomes.

Moreover, recent studies have begun to explore the role of 1-Naphthalenecarboxaldehyde 4-(trifluoromethyl) in materials science applications beyond pharmaceuticals. Its unique electronic properties make it a candidate for use in organic electronics, where it could contribute to the development of more efficient light-emitting diodes (LEDs) or photovoltaic cells. The ability to precisely control molecular architecture through fluorination allows researchers to tailor optical and electronic characteristics for specific applications.

In conclusion, 1-Naphthalenecarboxaldehyde 4-(trifluoromethyl) (CAS No. 1261596-97-7) represents a fascinating compound with broad utility in both academic research and industrial applications. Its structural features—combining a naphthalene core with a formyl group and a trifluoromethyl substituent—endow it with unique chemical properties that make it indispensable in drug discovery programs targeting various diseases. As research continues to uncover new synthetic methodologies and biological functions associated with fluorinated aromatic systems, compounds like this will undoubtedly play an increasingly pivotal role in shaping the future of medicinal chemistry.

• 454-89-7(3-(Trifluoromethyl)benzaldehyde)
• 401-95-6(3,5-Bis(trifluoromethyl)benzaldehyde)
• 46061-29-4(Methylium, oxo[4-(trifluoromethyl)phenyl]- (9CI))
• 1261456-87-4(2-(Difluoromethyl)naphthalene-4-carboxaldehyde)
• 1261676-74-7(1-(Difluoromethyl)naphthalene-5-carboxaldehyde)
• 455-19-6(4-(Trifluoromethyl)benzaldehyde)
• 1261660-97-2(1-(Difluoromethyl)naphthalene-7-carboxaldehyde)
• 92270-09-2(Methylium, [3,5-bis(trifluoromethyl)phenyl]oxo-)
• 46060-47-3(Methylium, oxo[3-(trifluoromethyl)phenyl]-)
• 116070-39-4(3-methyl-5-(trifluoromethyl)benzaldehyde)